Merit Medical Systems executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105M. EndoGastric Solutions’ EsophyX Z+ device delivers a durable, minimally invasive non-pharmacological treatment option for patients suffering from GERD. GERD is a digestive disorder that occurs when the lower esophageal sphincter doesn’t tighten correctly, allowing acid from the stomach to enter the esophagus. When this occurs chronically, it can result in serious health conditions, such as esophageal damage and cancer. The EsophyX Z+ device treats GERD by restoring the body’s reflux barrier.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
- Merit Medical initiated with an Outperform at Baird
- Merit Medical management to meet with Barrington
- Merit Medical Systems to Announce Second Quarter 2024 Results on August 1, 2024
- Merit Medical Launches basixSKY™ Inflation Device